Izalontamab brengitecan versus platinum-based chemotherapy in EGFR-mutated advanced non-squamous non-small-cell lung cancer after progression on third-generation EGFR tyrosine kinase inhibitors (PANKU-Lung01): a multicentre, randomised, open-label, phase 3 trial in China.
A targeted antibody-drug combination extends survival for lung cancer patients who've exhausted standard options, though with more side effects than chemotherapy.
Izalontamab brengitecan (iza-bren) is a first-in-class bispecific antibody-drug conjugate targeting epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3) and has shown antitumour activity in EGFR-mutated non-small-cell lung cancer (NSCLC). In participants with EGFR-mutated advanced non-squamous NSCLC after progression on third-generation EGFR TKIs, iza-bren significantly prolonged progression-free survival, although treatment-related adverse events of grade 3 or worse were more frequent than with chemotherapy.
What the study was
- Study design
- Randomized controlled trial
- Sample size
- 217
- Category
- Treatment Innovation
- Maturity
- Potentially Practice-Changing
- Journal
- Lancet
Why it surfaced
Randomized controlled trial; human evidence; PubMed abstract reviewed; conservative rubric score 10/10.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.